ESTRO 2024 - Abstract Book

S2446

Clinical - Urology

ESTRO 2024

Little is known about modalities of use of androgen deprivation therapy (ADT), like triptorelin (TRI), in patients with prostate cancer (PCa) in real life. Our purpose was to study compliance to a 12-month (m) TRI treatment (Tt), overall and by subgroups of circumstance of prescription.

Material/Methods:

Between November 2020 and November 2022, a prospective, multicenter, non-interventional study was conducted in France (TALISMAN, NCT04593420). Patients (pts) with histologically confirmed PCa, eligible for a ≥ 12 -month TRI Tt within its label were enrolled. Primary objective was to describe the proportion of patients treated continuously with TRI during 12 m following TRI Tt initiation. Secondary objectives included description of planned total duration of TRI Tt, reasons of choice of the planned total duration of TRI Tt and subgroup analysis by circumstance of prescription.

Results:

The final analysis included 787 pts (full analysis set population, FAS), mostly included by urologists (54.9%) and radiation oncologists (42.6%). Main baseline parameters overall and by circumstance of prescription are presented in Table (except for ‘other circumstance’, 31 patients (3.9%)). High risk localized [HRL] (41.1%) and metastatic stage [MS] (26.4%) were the main circumstances. Main planned total duration of TRI Tt were: [24-36] months in HRL and locally advanced (LA), [12-18[ months in biochemical recurrence (BR), for life in MS. Main reasons of choice of the planned total duration of TRI Tt were Gleason score in HRL and LA, PSA level in BCR and number of bone metastases in MS. Supportive care was provided to 60.1% overall at baseline, the highest frequency being in MS. After 12 m, 671 (85.3%) patients overall had been treated continuously with TRI Tt. This proportion was similar in all subgroups: 85.4% in HRL, 84.4% in LA, 90.6% in BR and 83.6% in MS. There were no new or unexpected safety findings identified during the study.

Baseline parameters by circumstance of prescription

High

risk

Locally advanced (n=128)

Biochemical recurrence

Metastatic stage

Overall (n=787)

localized (n=323)

(n=96)

(n=207)

Specialty of investigator (%)

- Urologist

42.1

64.1

56.3

70.5

54.9

- Radiation oncologist

57.3

35.2

43.8

21.7

42.6

- Medical oncologist

0.6

0.8

0

7.7

2.5

Age (years), mean (SD) Comorbidities (≥ 1) (%) Planned total duration of TRI Tt (%)

73.7 (7.0)

73.7 (8.3)

73.9 (8.6)

74.5 (8.4)

74.0 (7.9)

77.1

73.2

69.8

69.4

73.0

- [12-18[ months

15.8

26.6

38.5

18.4

21.6